AIA Group Ltd Decreases Position in HUTCHMED (China) Limited (NASDAQ:HCM)

AIA Group Ltd lessened its holdings in HUTCHMED (China) Limited (NASDAQ:HCM) by 4.1% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 375,078 shares of the company’s stock after selling 16,200 shares during the period. AIA Group Ltd’s holdings in HUTCHMED were worth $6,301,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in HCM. Hsbc Holdings PLC boosted its position in HUTCHMED by 821.2% in the 4th quarter. Hsbc Holdings PLC now owns 206,544 shares of the company’s stock valued at $3,720,000 after buying an additional 184,123 shares during the period. BNP Paribas Financial Markets boosted its position in HUTCHMED by 54.9% in the 1st quarter. BNP Paribas Financial Markets now owns 42,926 shares of the company’s stock valued at $721,000 after buying an additional 15,221 shares during the period. Baillie Gifford & Co. boosted its position in HUTCHMED by 7.2% in the 4th quarter. Baillie Gifford & Co. now owns 144,969 shares of the company’s stock valued at $2,625,000 after buying an additional 9,694 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in HUTCHMED by 353.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,593 shares of the company’s stock valued at $65,000 after buying an additional 2,801 shares during the period. Finally, Hennion & Walsh Asset Management Inc. boosted its position in HUTCHMED by 2.5% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 57,010 shares of the company’s stock valued at $958,000 after buying an additional 1,388 shares during the period. Hedge funds and other institutional investors own 8.82% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com raised shares of HUTCHMED from a “hold” rating to a “buy” rating in a research report on Monday, June 10th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $29.70.

HUTCHMED Trading Up 9.1 %

Shares of HUTCHMED stock traded up $1.62 during trading on Friday, hitting $19.40. 661,541 shares of the stock were exchanged, compared to its average volume of 128,689. The firm’s 50-day moving average price is $18.66 and its 200 day moving average price is $16.92. HUTCHMED has a 12-month low of $11.93 and a 12-month high of $21.92. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.72 and a quick ratio of 2.60.

About HUTCHMED

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.